Bromocriptine value in the treatment of patients with peripartum cardiomyopathy

Abstract

A peripartum cardiomyopathy is a relatively rare heart disease that affects women in the third trimester of pregnancy and/or after giving birth, characterized by high variability of the course and prognosis with the potential for full restoration of left ventricular function. The pathophysiological mechanism in this disease is associated with prolactin degradation disorder, and therefore, the medications that suppress lactation have promising clinical significance.